Farmas USA

Supongo que te refieres a superar la MM50 con la MM26 que lleva todo el año pasado y este por debajo. En cuanto a lo del rumbo alcista, yo la veo dentro de un canal que la lleva por arriba hasta la zona de los 5,00$ y por debajo a la de los 2,25$ aprox. , ahora estaría en tierra de nadie.
Al menos así lo veo.

THLD

perdon, seguidor, queria decir la MM200 en diario, ahi por los 3,74 ... hay que recuperarla

lo del rumbo alcista pues porque lleva 5 sesiones consecutivas cerrando mas arriba que la previa

THLD

Amrn

Te quiero,con tus caprichos,tus problemas,tus cambios de humor,tus pretendientes.....

Mucho post para guardar aqui,cada dia uno menos :).

GO!

AMRN

Proximo objeetivo, testear los 1,78

In My Opinion

NVAX, proximo objetivo ... MM50, los 8,54

MNKD

Que feo. Marco gaps por abajo, por si acaso ...

Está bajada seguro que esconde algo

La compañia no ha dado cifras de ventas del Q1.

OCULTISMO Y FALTA DE TRANSPARENCIA.

MNKD

Whether or not MannKind Corporation topped estimates last quarter is largely a matter of perspective. The loss of eight cents per share of MNKD was in line with some estimates, andactually topped others. Though the company didn’t offer an official revenue number for its first quarter, it did confirm it booked $7.1 million worth of AFREZZA shipments as deferred product sales, which could arguably substitute for sales, which would have topped estimates.

It’s not the Q1 numbers, however, that sent MNKD shares more than 5% lower on Friday. It was the lack of visibility and guidance. While most of the market understands it’s a new enterprise and any guidance is only offered on a best-guess basis, the company’s management seems oddly unconcerned about the slow launch and growing debt.

Investors may be increasingly concerned that not everything is as hunky-dory as was once believed.